Literature DB >> 16539372

Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.

Qing Huai1, Yingjie Sun, Huanchen Wang, Dwight Macdonald, Renée Aspiotis, Howard Robinson, Zheng Huang, Hengming Ke.   

Abstract

Type 4 phosphodiesterase (PDE4) inhibitors are emerging as new treatments for a number of disorders including asthma and chronic obstructive pulmonary disease. Here we report the biochemical characterization on the second generation inhibitor (+)-1 (L-, IC50=0.4 nM) and its enantiomer (-)-1 (L-, IC50=43 nM) and their cocrystal structures with PDE4D at 2.0 A resolution. Despite the 107-fold affinity difference, both enantiomers interact with the same sets of residues in the rigid active site. The weaker (-)-1 adopts an unfavorable conformation to preserve the pivotal interactions between the Mg-bound waters and the N-oxide of pyridine. These structures support a model in which inhibitors are anchored by the invariant glutamine at one end and the metal-pocket residues at another end. This model provides explanations for most of the observed structure-activity relationship and the metal ion dependency of the catechol-ether based inhibitors and should facilitate their further design.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16539372      PMCID: PMC2527038          DOI: 10.1021/jm051273d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  38 in total

1.  Conformational difference between PDE4 apoenzyme and holoenzyme.

Authors:  F Laliberté; Y Han; A Govindarajan; A Giroux; S Liu; B Bobechko; P Lario; A Bartlett; E Gorseth; M Gresser; Z Huang
Journal:  Biochemistry       Date:  2000-05-30       Impact factor: 3.162

Review 2.  New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease.

Authors:  M S Barnette; D C Underwood
Journal:  Curr Opin Pulm Med       Date:  2000-03       Impact factor: 3.155

3.  Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.

Authors:  André Iffland; Darcy Kohls; Simon Low; Jing Luan; Yan Zhang; Michael Kothe; Qing Cao; Ajith V Kamath; Yuan-Hua Ding; Tom Ellenberger
Journal:  Biochemistry       Date:  2005-06-14       Impact factor: 3.162

Review 4.  Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.

Authors:  V Dal Piaz; M P Giovannoni
Journal:  Eur J Med Chem       Date:  2000-05       Impact factor: 6.514

Review 5.  Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

Authors:  Brian J Lipworth
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

6.  Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.

Authors:  Robert X Xu; Warren J Rocque; Millard H Lambert; Dana E Vanderwall; Michael A Luther; Robert T Nolte
Journal:  J Mol Biol       Date:  2004-03-19       Impact factor: 5.469

7.  Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.

Authors:  Richard W Friesen; Yves Ducharme; Richard G Ball; Marc Blouin; Louise Boulet; Bernard Côté; Richard Frenette; Mario Girard; Daniel Guay; Zheng Huang; Thomas R Jones; France Laliberté; Joseph J Lynch; Joseph Mancini; Evelyn Martins; Paul Masson; Eric Muise; Douglas J Pon; Peter K S Siegl; Angela Styhler; Nancy N Tsou; Mervyn J Turner; Robert N Young; Yves Girard
Journal:  J Med Chem       Date:  2003-06-05       Impact factor: 7.446

Review 8.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

Authors:  Miles D Houslay; David R Adams
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

9.  Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.

Authors:  Richard Frenette; Marc Blouin; Christine Brideau; Nathalie Chauret; Yves Ducharme; Richard W Friesen; Pierre Hamel; Tom R Jones; France Laliberté; Chun Li; Paul Masson; Malia McAuliffe; Yves Girard
Journal:  Bioorg Med Chem Lett       Date:  2002-10-21       Impact factor: 2.823

10.  Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.

Authors:  Byung-Je Sung; Kwang Yeon Hwang; Young Ho Jeon; J I Lee; Yong-Seok Heo; Jin Hwan Kim; Jinho Moon; Jung Min Yoon; Young-Lan Hyun; Eunmi Kim; Sung Jin Eum; Sam-Yong Park; Jie-Oh Lee; Tae Gyu Lee; Seonggu Ro; Joong Myung Cho
Journal:  Nature       Date:  2003-09-04       Impact factor: 49.962

View more
  3 in total

Review 1.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

2.  Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity.

Authors:  Huanchen Wang; Zier Yan; Serena Yang; Jiwen Cai; Howard Robinson; Hengming Ke
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162

3.  Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).

Authors:  Ryan T Cameron; Ryan G Coleman; Jon P Day; Krishna C Yalla; Miles D Houslay; David R Adams; Brian K Shoichet; George S Baillie
Journal:  Biochem Pharmacol       Date:  2013-03-05       Impact factor: 5.858

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.